Hayashi Saeko, Kitamura Yohei, Hirose Yuichi, Yoshida Kazunari, Sasaki Hikaru
Department of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan.
Department of Neurosurgery, Saiseikai Utsunomiya Hospital, 911-1 Takebayashi, Utsunomiya, Tochigi, Japan.
J Neurooncol. 2017 Mar;132(1):119-126. doi: 10.1007/s11060-016-2344-1. Epub 2016 Dec 26.
Although 1p19q codeleted gliomas are the most favorable molecular subgroup of lower-grade gliomas, there are cases with early recurrence or short survival. The objective of this study was to elucidate molecular-genetic and clinicopathological prognostic factors in patients with gliomas showing total 1p19q loss. The study included 57 consecutive patients with codeleted gliomas who were operated at Keio University Hospital between 1990 and 2010. These patients were assessed for chromosomal copy number aberrations, promoter methylation status of the O6-methylguanine-DNA methyltransferase gene (MGMT), and demographic and clinicopathological prognostic factors in diffuse gliomas. No significant difference was observed in the overall survival (OS) of the patients with respect to age (≥40 years vs. <40 years), degree of resection, maximum tumor diameter (≥5 cm vs. <5 cm), histological subtype, and MGMT promoter methylation status. Gain of chromosome 19p and grade III histology were associated with shorter OS (P = 0.019, 0.061, respectively). Gain of 19p and histological grade III might be negative prognostic factors for the patients with gliomas showing total 1p19q loss. Further investigation is warranted to confirm these notions.
尽管1p19q共缺失型胶质瘤是低级别胶质瘤中最有利的分子亚组，但仍有一些病例会早期复发或生存期短。本研究的目的是阐明显示1p19q完全缺失的胶质瘤患者的分子遗传学和临床病理预后因素。该研究纳入了1990年至2010年间在庆应义塾大学医院接受手术的57例连续的共缺失型胶质瘤患者。对这些患者进行了染色体拷贝数畸变、O6-甲基鸟嘌呤-DNA甲基转移酶基因（MGMT）的启动子甲基化状态以及弥漫性胶质瘤的人口统计学和临床病理预后因素评估。在患者的总生存期（OS）方面，未观察到年龄（≥40岁与<40岁）、切除程度、最大肿瘤直径（≥5 cm与<5 cm）、组织学亚型和MGMT启动子甲基化状态之间存在显著差异。19p染色体获得和III级组织学与较短的OS相关（P分别为0.019、0.061）。19p获得和组织学III级可能是显示1p19q完全缺失的胶质瘤患者的不良预后因素。有必要进行进一步研究以证实这些观点。
